Drug for Neglected Diseases Working Group Meeting
Rio de Janeiro, Brazil, 2-3, December 2002
Monday 2 December 2002
08:30 - 09:00 Registration
09:00 - 10:00 1st Plenary Session
Welcome, introduction and update
Chair: Dr James Orbinski, Médecins sans Frontières (MSF), Campaign for Access to Essential Medicines, Canada
Welcome and Introduction
Dr Paulo Buss, President Fiocruz, Brazil
Overview of the achievements of the Access Campaign and DND Working Group over the last three years, and future challenges.
Dr Bernard Pécoul, Director of the MSF Campaign for Access to Essential Medicines, Switzerland
Update on the DNDi
Dr Yves Champey, Director DNDi feasibility study, France
10:00 - 11:00 2nd Plenary Session
Who's driving the R&D agenda?
Chair: Dr Ayoade Oduola, Programme for Research and Training in Tropical Diseases (TDR), Switzerland
How to translate scientific progress into health tools that meet the needs of poor people
Dr Carlos Morel, Director, WHO - Programme for Research and Training in Tropical Diseases (TDR), Switzerland
Does pharmaceutical innovation address priority health needs? Are we getting our money's worth?
Dr Graham Dukes, University of Oslo, Norway
11:00-11:30 Coffee Break
11:30-13:00 2nd Plenary Session
Can public, academic and other non-profit researchers be mobilized to do more needs-driven research? If so, how?
Dr Motlalepula Gilbert Matsabisa, Medical Research Council, South Africa
Dr Vasantha Muthuswamy, Indian Council of Medical Research, India
Dr Pierre Druilhe, Institut Pasteur, France
13:00 -14:30 Lunch
14:30 -16:00 3rd Plenary Session
Regulatory Barriers to R&D for Neglected Diseases?
Chair: Prof Kris Weerasuryia, Sri Lanka
Weighing benefits and risks in medical research for neglected diseases
Prof Solomon Benatar, Bioethics Centre, University of Cape Town, South Africa
Does global harmonisation of regulatory requirements constrain the evaluation and availability of new drugs for neglected diseases?
Prof Patrice Trouiller, University of Grenoble, France
Defining essential regulatory issues for R&D for neglected diseases
Dr Gonzalo Vecina Neto, Director of ANVISA ( National Agency for Health Vigilance), Brazil
End of Day One
16:00-16:30 Transportation to the Theatre de la Maison de France
Tuesday December 3, 2002
08:30-10:30 4th Plenary Session
Research capacity, production capacity and technology transfer
Chair: Dr Eloan dos Santos Pinheiro, Far-Manguinhos, Brazil
Co-chair: Michel Lotrowska, MSF, Campaign for Access to Essential Medicines, Brazil
Technology transfer and the TRIPS Agreement: what are the obligations of the industrialized world, and what is actually happening?
Prof Fred Abbott, Florida State University College of Law, USA
Research Capacity in Africa: more than a place to do clinical trials.
Dr Monique Wasunna, Kenya Medical Research Institute, Kenya
Why is innovation in the public sector necessary? Is it feasible?
Case of fixed-dose combination ARVs.
Dr Krisana Kraisintu, Government Pharmaceutical Organization (GPO), Thailand
Pharmaceutical Technology transfer to Africa: a key to sustainable solutions
Dr Giorgio Roscigno, Global Alliance for Tuberculosis Drug Development, Belgium
10:30 11:00 Coffee Break
11:00-13:00 Simultaneous Breakout Sessions
1. Knowledge management and intellectual property strategies for not-for-profit drug development
- Chair: Dr Motlalepula Gilbert Matsabisa, Medical Research Council, South Africa
- Introduction: Dr Sibongile Pefile, Centre for the Management of Intellectual Property in Health Research & Development (MIHR), USA
2. R&D for Neglected Diseases: Incentives and policy changes to mobilize public and academic sector scientists and their institutions (North/South)
- Chair: Dr Fernando de Nielander Ribeiro, Director of FINEP, Brazil
- Introduction: Dr Simon Croft, London School of Hygiene and Tropical Medicine, UK
Discussant: Dr Jean Claude Dujardin, Institute for Tropical Medicine, Belgium
3. The Cases of W 135 meningitis vaccine, and the rotavirus vaccine: Strategies to encourage health needs-driven R&D.
- Chair: Dr Akira Homma, BioManguinhos, Brazil
- Introduction: Dr Philippe Guérin, Norwegian Institute of Public Health, Norway
4. What are the issues and implications of increased spending on biowarfare for R&D for Neglected Diseases?
- Chair: Dr Robert Ridley, WHO - Programme for Research and Training in Tropical Diseases (TDR), Switzerland
- Introduction: Background document prepared by Prof David Fidler, Indiana University Law School, USA, introduction by Ellen 't Hoen, MSF, Campaign for Access to Essential Medicines, France
14:30-15:30 Reports of the breakout sessions
Chair: Prof. Dyann Wirth, Director, Harvard School of Public Health, USA
15:30-16:30 5th Plenary Session
Changing the global rules: how to create a system to address development of and assess to effective tools to combat neglected diseases?
Chair: Sakiko Fukuda-Parr, United Nations Development Programme (UNDP), USA
Co-Chair: Dr Jorge Bermudez, Oswaldo Cruz Foundation, Brazil
Public sector R&D: is it a different paradigm?
Dr Yongyuth Yuthavong, Institute of Sciences and Technologies, Thailand
Are Public Private Partnerships the Answer? Lessons from GAVI.
Mary Starling, London School of Hygiene & Tropical Medicine, UK
16:15 - 16:45 Coffee Break
16:45 - 18:00 5th Plenary Session (continuation)
Is there a role for IP in stimulating needs-driven R&D in developing countries? Recommendations from the UK Commission on IPR.
Charles Clift, Commission on Intellectual Property Rights, UK
What alternative frameworks could be developed to finance R&D that would address real health needs?
James Love, Consumer Project on Technology, USA
18:00-18:30 Reinventing the working group: promoting the development of innovative strategies and medical solutions to address the health needs of neglected patients.
Chair: Dr Els Torreele, MSF, Campaign for Access to Essential Medicines, Belgium
18:30 Closure of the meeting
Dr. James Orbinski, Médecins Sans Frontières (MSF), Campaign for Access to Essential Medicine, Canada